ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Late Effects In Breast Cancer Treatment Found In Study

January 25, 2002

Recombinant TSH Avoids Need To Stop Replacement Therapy

January 27, 2006

In Brief: FDA Opens Advisory Committee Consideration Of NDAs, Finds Discussion Is Not Inhibited

September 10, 1976

In Brief: Ozer, Comis Join Allegheny Cancer Centers; Two Cooperative Groups Under Same Roof

March 21, 1997

No difference between digital or film mammograms, study finds.

September 23, 2005

Clinical Trials: Stories On Results Can Have Unintended Consequences

May 15, 1998